Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics

References

• Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. doi:10.1038/nrd4624
   PubMed Web of Science ®Google Scholar
• Bachert C, Zhang N, Hellings PW, Bousquet J. Endotype-driven care pathways in patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2018;141(5):1543–1551. doi:10.1016/j.jaci.2018.03.004
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Aljamil N, Roxas C, et al. P48 The ‘T2-low’ asthma phenotype: could it just be T2-high asthma treated with corticosteroids? Thorax. 2018;73:A124–A125.
   Web of Science ®Google Scholar
• Khan A, Vandeplas G, Huynh TMT, et al. The Global Allergy and Asthma European Network (GALEN) rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32–42. doi:10.4193/Rhin17.255
   PubMed Web of Science ®Google Scholar
• Philpott C, Ta NH, Hopkins C, et al. Socioeconomic, comorbidity, lifestyle, and quality of life comparisons between chronic rhinosinusitis phenotypes. Laryngoscope. 2021;131(10):2179–2186. doi:10.1002/lary.29527
   PubMed Web of Science ®Google Scholar
• Busse WW, Kraft M, Rabe KF, et al. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J. 2021;58(2):2003393. doi:10.1183/13993003.03393-2020
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9(3):1133–1141. doi:10.1016/j.jaip.2020.09.063
   PubMed Web of Science ®Google Scholar
• Bachert C, Bhattacharyya N, Desrosiers M, Khan AH. Burden of disease in chronic rhinosinusitis with nasal polyps. J Asthma Allergy. 2021;14:127–134. doi:10.2147/JAA.S290424
   PubMed Web of Science ®Google Scholar
• Bhattacharyya N, Villeneuve S, Joish VN, et al. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope. 2019;129(9):1969–1975. doi:10.1002/lary.27852
   PubMed Web of Science ®Google Scholar
• Khan A, Huynh TMT, Vandeplas G, et al. The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life. Rhinology. 2019;57(5):343–351. doi:10.4193/Rhin19.158
   PubMed Web of Science ®Google Scholar
• de Groot JC, Ten Brinke A, Bel EH. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1(1):00024–2015. doi:10.1183/23120541.00024-2015
   PubMedGoogle Scholar
• Meltzer EO, Busse WW, Wenzel SE, et al. Use of the asthma control questionnaire to predict future risk of asthma exacerbation. J Allergy Clin Immunol. 2011;127(1):167–172. doi:10.1016/j.jaci.2010.08.042
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Globe G, Ghushchyan VH, Campbell JD, Bender B, Magid DJ. Exploring asthma control cutoffs and economic outcomes using the Asthma Control Questionnaire. Ann Allergy Asthma Immunol. 2016;117(3):251–257.e252. doi:10.1016/j.anai.2016.07.020
   PubMed Web of Science ®Google Scholar
• Tupper OD, Ulrik CS. Long-term predictors of severe exacerbations and mortality in a cohort of well-characterised adults with asthma. Respir Res. 2021;22(1):269. doi:10.1186/s12931-021-01864-z
   PubMed Web of Science ®Google Scholar
• Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. Allergy. 2019;74(1):28–39. doi:10.1111/all.13599
   PubMed Web of Science ®Google Scholar
• Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. doi:10.1080/1744666X.2017.1298443
   PubMed Web of Science ®Google Scholar
• Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–1204. doi:10.1111/all.14151
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–1650. doi:10.1016/S0140-6736(19)31881-1
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Bachert C, Amin N, et al. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma. Ann Allergy Asthma Immunol. 2021;126(5):584–592.e581. doi:10.1016/j.anai.2021.01.012
   PubMed Web of Science ®Google Scholar
• Gevaert P, Lee SE, Settipane RA, et al. Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps. Clin Transl Immunology. 2023;12(1):e1433. doi:10.1002/cti2.1433
   PubMed Web of Science ®Google Scholar
• Muraro A, Lemanske RF, Hellings PW, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1347–1358. doi:10.1016/j.jaci.2016.03.010
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol. 2021;147(1):29–36. doi:10.1016/j.jaci.2020.11.013
   PubMed Web of Science ®Google Scholar
• Khan A, Reaney M, Guillemin I, et al. Development of Sinonasal Outcome Test (SNOT-22) domains in chronic rhinosinusitis with nasal polyps. Laryngoscope. 2022;132(5):933–941. doi:10.1002/lary.29766
   PubMed Web of Science ®Google Scholar
• Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009;34(5):447–454. doi:10.1111/j.1749-4486.2009.01995.x
   PubMed Web of Science ®Google Scholar
• Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99(5):553–558. doi:10.1016/j.rmed.2004.10.008
   PubMed Web of Science ®Google Scholar
• Canonica GW, Blasi F, Crimi N, et al. Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis. Clin Mol Allergy. 2021;19(1):5. doi:10.1186/s12948-021-00146-9
   PubMedGoogle Scholar
• Busse WW, Wenzel SE, Casale TB, et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021;9(10):1165–1173. doi:10.1016/S2213-2600(21)00124-7
   PubMed Web of Science ®Google Scholar
• Couillard S, Laugerud A, Jabeen M, et al. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax. 2022;77(2):199–202. doi:10.1136/thoraxjnl-2021-217325
   PubMed Web of Science ®Google Scholar
• Pavord I, Busse W, Corren J, et al. P220 baseline exhaled nitric oxide (FeNO) as predictor of response to dupilumab in uncontrolled, moderate-to-severe asthma. Ann Allergy Asthma Immunol. 2020;125(5):S34. doi:10.1016/j.anai.2020.08.117
   Web of Science ®Google Scholar
• Pavord I, Brusselle G, Jackson D, et al. FeNO as a potential prognostic and predictive marker of lung function decline in patients with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST. American Thoracic Society – 118th International Conference; 2022.
   Google Scholar
• Heffler E, Saccheri F, Bartezaghi M, Canonica GW. Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis. Clin Transl Allergy. 2020;10:25. doi:10.1186/s13601-020-00330-1
   PubMed Web of Science ®Google Scholar
• D’Amato M, Menzella F, Altieri E, et al. Benralizumab in patients with severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: an ANANKE study post-hoc analysis. Front Allergy. 2022;3:881218. doi:10.3389/falgy.2022.881218
   PubMedGoogle Scholar
• Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020;50(7):789–798. doi:10.1111/cea.13614
   PubMed Web of Science ®Google Scholar
• Campisi R, Crimi C, Nolasco S, et al. Real-world experience with dupilumab in severe asthma: one-year data from an Italian named patient program. J Asthma Allergy. 2021;14:575–583. doi:10.2147/JAA.S312123
   PubMed Web of Science ®Google Scholar
• Minagawa S, Araya J, Watanabe N, et al. Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP. BMC Pulm Med. 2022;22(1):258. doi:10.1186/s12890-022-02046-3
   PubMed Web of Science ®Google Scholar
• Nolasco S, Crimi C, Pelaia C, et al. Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study. J Allergy Clin Immunol Pract. 2021;9(12):4371–4380 e4374. doi:10.1016/j.jaip.2021.08.004
   PubMed Web of Science ®Google Scholar
• Lombardo N, Pelaia C, Ciriolo M, et al. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. Int J Immunopathol Pharmacol. 2020;34:2058738420950851. doi:10.1177/2058738420950851
   Web of Science ®Google Scholar
• Detoraki A, Tremante E, D’Amato M, et al. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study. Ther Adv Respir Dis. 2021;15:17534666211009398. doi:10.1177/17534666211009398
   Web of Science ®Google Scholar
• Gallo S, Castelnuovo P, Spirito L, et al. Mepolizumab improves outcomes of chronic rhinosinusitis with nasal polyps in severe asthmatic patients: a multicentric real-life study. J Pers Med. 2022;12(8):1304. doi:10.3390/jpm12081304
   PubMed Web of Science ®Google Scholar
• Bidder T, Sahota J, Rennie C, Lund VJ, Robinson DS, Kariyawasam HH. Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study. Rhinology. 2018;56(1):42–45. doi:10.4193/Rhin17.139
   PubMed Web of Science ®Google Scholar